ESSA Pharma Inc (EPIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ESSA Pharma Inc (EPIX) has a cash flow conversion efficiency ratio of -0.039x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.20 Million) by net assets ($108.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ESSA Pharma Inc (EPIX) defensive interval to measure how many days the company can operate on defensive assets alone.
ESSA Pharma Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how ESSA Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ESSA Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ESSA Pharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cinevista Limited
NSE:CINEVISTA
|
0.054x |
|
RS Public Company Limited
BK:RS
|
-0.051x |
|
Oncosil Medical Ltd
AU:OSL
|
-1.814x |
|
Metalsgrove Mining Ltd
AU:MGA
|
-0.095x |
|
Viking Mines Ltd
AU:VKA
|
-0.290x |
|
Pets at Home Group Plc
LSE:PETS
|
0.086x |
|
Mainz Biomed BV
NASDAQ:MYNZ
|
-6.957x |
|
Pryme BV
OL:PRYME
|
-1.603x |
Annual Cash Flow Conversion Efficiency for ESSA Pharma Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ESSA Pharma Inc (EPIX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $124.61 Million | $-22.72 Million | -0.182x | -34.21% |
| 2023-09-30 | $145.63 Million | $-19.78 Million | -0.136x | +20.91% |
| 2022-09-30 | $167.12 Million | $-28.70 Million | -0.172x | -31.11% |
| 2021-09-30 | $194.01 Million | $-25.42 Million | -0.131x | +38.87% |
| 2020-09-30 | $79.24 Million | $-16.98 Million | -0.214x | +13.96% |
| 2019-09-30 | $49.18 Million | $-12.25 Million | -0.249x | +77.69% |
| 2018-09-30 | $9.15 Million | $-10.22 Million | -1.116x | -127.50% |
| 2017-09-30 | $-4.27 Million | $-17.35 Million | 4.061x | -85.75% |
| 2016-09-30 | $-537.00K | $-15.30 Million | 28.493x | +1125.81% |
| 2015-09-30 | $4.43 Million | $-12.30 Million | -2.778x | -163.48% |
| 2014-09-30 | $1.97 Million | $-2.08 Million | -1.054x | -66058.28% |
| 2013-09-30 | $479.04K | $-763.35 | -0.002x | +99.89% |
| 2012-09-30 | $1.31K | $-1.82K | -1.396x | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.